Is there a role for antibiotic cycling in the intensive care unit?

Critical Care Medicine

Volumn 29, Issue 4 SUPPL., 2001, Pages

  Kollef, M H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Bacteria; Hospital; Infection; Intensive care unit; Nosocomial; Outcomes; Prevention; Resistance

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DRUG UTILIZATION; HEALTH CARE COST; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0035045672     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200104001-00014     Document Type: Review

References (87)

1. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership
2. Antibiotic resistance in the intensive care unit setting
3. Antimicrobial-drug resistance
4. Antibiotic cycling: Is it ready for prime time?
5. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay
6. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients
7. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia
8. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit
9. The value of routine microbial investigation in ventilator-associated pneumonia
10. The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia
11. Staphylococcus aureus: A well-armed pathogen
12. Arthritis and sepsis caused by Staphylococcus aureus: Can the tissue injury be reduced by modulating the host's immune response?
13. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes
14. Resistance to methicillin and virulence of Staphylococcus aureus strains in bacteremic cancer patients
15. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms
16. Cell-to-Cell signaling and Pseudomonas aeruginosa infections
17. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia
18. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient
19. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia
20. Clinical implications of nosocomial Gram-positive bacteremia and superimposed antimicrobial resistance
21. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
22. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation
23. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults
24. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes
25. Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin
26. Analysis of 1186 episodes of Gram-negative bacteremia in non-university hospitals: The effects of antimicrobial therapy
27. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy
28. Enterococcal bacteremia in the surgical intensive care unit. Does vancomycin resistance affect mortality?
29. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: Comparison of clinical features and outcomes
30. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: Impact of intravascular devices and methicillin resistance
31. Consequences of bacterial resistance to antibiotics in medical practice
32. Epidemiology of drug resistance: Implications for a post-antimicrobial era
33. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa
34. Health and economic impact of antimicrobial resistance
35. Bug-drug resistance: Sometimes less is more
36. Pneumonia caused by penicillinnon-susceptible and penicillin-susceptible pneumococci in adults: A case-control study
37. A novel antimicrobial agent joins the battle against resistant bacteria
38. The role of fundamental research and biotechnology in finding solutions to the global problem of antibiotic resistance
39. Antibiotic resistance: A view from the pharmaceutical industry
40. The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance
41. Multidrug resistance - A sign of the times
42. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries
43. Antimicrobial resistance rates among Gramnegative bacilli recovered from patients in intensive care units: Evaluation of a national post marketing surveillance program
44. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture technique
45. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients
46. Three-year multicenter surveillance of systemic pneumococcal infections in children
47. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection
48. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients
49. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella
50. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins
51. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype antratus
52. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria
53. Ventilator-associated pneumonia: A multivariate analysis
54. The effect of late-onset ventilator-associated pneumonia in determining patient mortality
55. Risk factors for ICU acquired pneumonia
56. Nosocomial infections in medical intensive care units in the United States
57. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control
58. Intermittent bolus dosing of ceftazidime in critically ill patients
59. The importance of antibiotic pharmacokinetics in critical illness
60. The future - Can we learn from the past?
61. Does antibiotic restriction prevent resistance?
62. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures
63. The effect of monitoring of antibiotic use on decreasing antibiotic resistance in the hospital
64. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study
65. Antimicrobial resistance with focus on betalactam resistance in Gram-negative bacilli
66. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veteran Affairs Medical Center
67. Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficile-associated diarrhea and cost
68. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci
69. Experience with a hospital-wide outbreak of vancomycin-resistant enterococci
70. A computer-assisted management program for antibiotics and other antiinfective agents
71. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality
72. Improving empiric antibiotic selection using computer decision support
73. Prospective surveillance of imipenem/cilastin use and associated seizures using a hospital information system
74. Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes
75. Antibiotic resistance - Squeezing the balloon?
76. Circumventing antibiotic resistance in specialized hospital units
77. Aminoglycoside resistance and aminoglycoside usage: Ten years of experience in one hospital
78. Scheduled rotation of antibiotic classes. A strategy to decrease the incidence of ventilator-associated pneumonia due to antibiotic-resistant gram-negative bacteria
79. Rotation and restricted use of antibiotics in a medical intensive care unit: Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria
80. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices
81. A pilot study of antibiotic cycling in a hematology-oncology unit
82. Antimicrobial resistance in intensive care units
83. Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU?
84. Evaluating treatment protocols to prevent antibiotic resistance
85. The microbial genetics of antibiotic cycling
86. Strategies for study of the role of cycling on antimicrobial use and resistance